Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 32, 06 March 2024
Open
Access | Article
Glucagon-like peptide-1 analogs for Alzheimer’s disease -- A systematic meta-analysis
* Author to whom correspondence should be addressed.
Abstract
Alzheimer’s Disease (AD) poses a serious health concern especially for the aging population above the years of 65. An estimated 6 million Americans are diagnosed with Alzheimer’s Disease, and there are at least 50 million Alzheimer’s patients in the world. AD affects the daily life of these patients, yet there is no permanent cure. Current treatments involve cholinesterase inhibitors and NMDA-receptor agonists to help alleviate the symptoms. GLP-1 is a peptide often used in the treatment of diabetes. Since there are shared pathological features between diabetes and AD, such as insulin dysfunction and glucose metabolism dysregulation, GLP-1 may be a viable study for AD treatment. To perform a meta-analysis to investigate whether GLP-1 has a beneficiary effect on biological markers and cognitive outcome in AD patients. We searched the following electronic databases: EMBASE, MEDLINE, phycINFO, CINAHL, PubMed, Cochrane CENTRAL, and ClinicalTrials.gov. We only utilized Randomized Control Trials (RCTs) and clinical trials. We also searched with the following Medical Search Headings: Alzheimer’s Disease, Alzheimer, Alzheimer’s, and GLP-1. We included 2 randomized, double-blind, and placebo controlled clinical trials into our meta-analysis. We extracted the baseline and outcomes from the clinical trials and evaluated its risks of bias. Biological markers were measured by amyloid beta (Aß) accumulation, and cognitive outcomes were measured by the Wechsler Memory Scale - Fourth Edition (WMS-IV) and Mini Mental State Exam (MMSE). For one study, the WMS-IV was used to measure cognitive outcome. The other study measured cognitive outcome with the MMSE. Biological markers were measured by Aß accumulation in one study and with [11C]PIB tracer in another. There was no significant difference between the placebo and experimental group after the treatment period.
Keywords
GLP-1, Alzheimer’s Disease, Meta-analysis, Systematic evaluation
References
1. Alzheimer’s A. 2014 Alzheimer’s disease facts and figures.
2. Tolnay M, Probst A. 1999. REVIEW: tau protein pathology in Alzheimer’s disease and related disorders. Europathol Appl Eurobiol.
3. Gandy S. 2005. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest.
4. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. 2002. Amyloid beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans.
5. Alavijeh MS, Chishty M, Qaiser MZ, Palmer MA, 2005. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx.
6. McGleenon B, Dynan K, Passmore A. 1999. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol.
7. Lipton S, Chen HS. 2004. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ.
8. Kim W, Egan JM. 2008. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev.
9. Nauck MA. 2004. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res.
10. Femminella GD, Edison P. 2014. Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimers Dement.
11. Chang YF, Zhang D, Hu WM, Liu DX, Li L. 2020. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apoptosis. J Clin Neurosci.
12. Batista AF, Forny-Germano L, Clarke JR, Silva NM, Brito-Moreira J, Boehnke SE, Winterborn A, Coe BC, Lablans A, Vital JF, et al. 2018. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease. J Pathol.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-321-0
- ISBN (Online)
- 978-1-83558-322-7
- Published Date
- 06 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/32/20240813
- Copyright
- 06 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited